Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
20 mars 2020 16h01 HE
|
Forty Seven, Inc.
-- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML ---- Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and...
Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia
11 mars 2020 08h00 HE
|
Forty Seven, Inc.
MENLO PARK, Calif. and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV) and Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) announced today that they have entered into a...
Forty Seven to Present at Upcoming Investor Conferences in March
25 févr. 2020 08h00 HE
|
Forty Seven, Inc.
MENLO PARK, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven to Present at Upcoming Investor Conferences in February
06 févr. 2020 08h00 HE
|
Forty Seven, Inc.
MENLO PARK, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven Announces 2020 Strategic Priorities and Expected Milestones
10 janv. 2020 08h00 HE
|
Forty Seven, Inc.
-- Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 -- -- Updated Data from Ongoing Phase 1b...
Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares
16 déc. 2019 16h01 HE
|
Forty Seven, Inc.
MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the closing of its previously announced public...
Forty Seven, Inc. Prices Underwritten Public Offering of 4,860,000 Shares of Common Stock
11 déc. 2019 22h32 HE
|
Forty Seven, Inc.
MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten...
Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock
11 déc. 2019 16h01 HE
|
Forty Seven, Inc.
MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced that it has commenced an underwritten public...
Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation
09 déc. 2019 10h00 HE
|
Forty Seven, Inc.
-- Expect to Initiate Phase 1 Clinical Trial in Healthy Volunteers in First Quarter of 2020 ---- Forty Seven to Host Investor Event and Webcast at 8:00 p.m. ET -- MENLO PARK, Calif., Dec. 09, 2019...
Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
09 déc. 2019 07h00 HE
|
Forty Seven, Inc.
-- CR Rate of 50% and ORR of 92% Observed in Untreated Patients with Higher-Risk MDS ---- CR/CRi Rate of 55% and ORR of 64% Observed in Patients with Untreated AML Who are Ineligible for Induction...